GlassScriptPhysician profile
Cassandra G Simms
NPI 1437117926
$4,739.20
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what 76% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $287 · 2021: $648 · 2022: $804 · 2023: $799 · 2024: $826 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $837.32 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $813.26 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $766.32 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $277.24 | 2019-2022 | |
| Tris Pharma INC | $265.06 | 2019-2023 | Dyanavel Xr |
| Lundbeck LLC | $256.60 | 2019-2025 | Rexulti, Brintellix |
| Abbvie INC. | $230.65 | 2021-2025 | Vraylar |
| Adlon Therapeutics L.P. | $229.44 | 2019-2021 | |
| Neos Therapeutics, LP | $222.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $144.70 | 2022-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $105.16 | 2019-2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $92.64 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.20 | 2023-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $73.66 | 2024-2025 | |
| Shire North American Group INC | $70.53 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $56.98 | 2021-2025 | Lybalvi, Aristada |
| Rhodes Pharmaceuticals L.P. | $45.20 | 2019 | |
| Neurocrine Biosciences, INC. | $38.04 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $36.39 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $23.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.64 | 2019 | |
| Allergan, INC. | $16.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2024 | Cobenfy |
| Almatica Pharma LLC | $15.31 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $14.60 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.